DDInter533 DDInter821
A commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity. Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases. Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders.
Diatrizoate {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Flucytosine
Flucytosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Diatrizoate {u} (Compound) causes {v} (Side Effect) Renal failure
Renal failure {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Givosiran
Diatrizoate {u} (Compound) is included by {v} (Pharmacologic Class) X-Ray Contrast Activity
X-Ray Contrast Activity {u} (Pharmacologic Class) includes {v} (Compound) Iohexol
Iohexol {u} may lead to a major life threatening interaction when taken with {v} Givosiran
Diatrizoate (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Flucytosine (Compound) and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Diatrizoate (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Givosiran
Diatrizoate (Compound) is included by X-Ray Contrast Activity (Pharmacologic Class) and X-Ray Contrast Activity (Pharmacologic Class) includes Iohexol (Compound) and Iohexol may lead to a major life threatening interaction when taken with Givosiran